Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockUpcoming Result Date: May 20, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stockMax Healthcare Institute Ltd (MAXHEALTH) is currently trading at 1,070.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Max Healthcare Institute Limited operates a network of multi‑speciality and super‑speciality hospitals, plus two strategic business units (Max Lab and Max@Home); the Group runs ~20 facilities with ~5,200 beds, combining owned, managed and partner hospitals across major Indian metros and select PPP arrangements in Punjab. Q3 FY26 network gross revenue reached ₹2,608 crore (+10% YoY) with Network Operating EBITDA of ₹648 crore (+4% YoY) and Network PAT of ₹344 crore (+9% YoY) after two exceptional items totaling ₹55 crore, reflecting steady profitability despite payor and regulatory headwinds. Max is aggressively expanding capacity: multiple brownfield towers were partially commissioned with strong early EBITDA margins (~31%–39%), a staggered acquisition in Pune for ~450 beds, and a roadmap to nearly double bed capacity over the next 4–5 years, implying significant future revenue visibility and capital deployment. Regulatory and payor dynamics materially affected margins this quarter: CGHS tariff revisions, discontinuation of high‑value patented chemotherapy for institutional patients, a GST rate change, and temporary disruption in cashless insurer services altered payor mix and lowered sequential EBITDA margins. Digital and adjacency businesses are meaningful: digital channels contributed ~₹803 crore (~31% of gross revenue) in Q3 and Max@Home and Max Lab posted robust growth (+23% and +13% YoY respectively), signalling diversified revenue streams and stronger patient acquisition funnels outside core inpatient services.
Over the past 52 weeks, Max Healthcare Institute Ltd has traded between a low of ₹903.50 and a high of ₹1,314.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Max Healthcare Institute Ltd has a market capitalization of approximately 1,03,825.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Max Healthcare Institute Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 73.16 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,03,825.65 Cr, Max Healthcare Institute Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Max Healthcare Institute Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Max Healthcare Institute Ltd is 73.16. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The material states the Q4 FY26 results are scheduled for May 2026 (Expected), for the period ended March 31, 2026.
The company scheduled the board meeting for February 5, 2026, to consider and approve unaudited results for the quarter and nine months ended December 31, 2025.
It proposed establishing five regional medical value tourism hubs through a public-private partnership model to promote India as a global healthcare destination.
The Budget proposed establishing five regional medical value tourism hubs through a public-private partnership (PPP) model to promote India as a global healthcare destination.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Litigation Disclosure
Max Healthcare disclosed that BRS Capital Two Pte Ltd filed an NCLT (Cuttack) petition alleging oppression and mismanagement against Kalinga Hospital Ltd, a subsidiary Max acquired ~58.28% of on May 18, 2026; matter listed May 19, order reserved; next hearing July 7, 2026.
NCLT Petition
Max Healthcare disclosed that BRS Capital Two Pte. Ltd. filed a petition at NCLT Cuttack under Sections 241/242 alleging oppression and mismanagement at Kalinga Hospital Ltd (58.28% stake acquired by Max on May 18, 2026); matter reserved, next hearing July 7, 2026; financial impact uncertain.
Acquisition update
Max Healthcare availed a senior secured term loan and acquired ~58.28% equity in 250‑bed Kalinga Hospital Ltd for ~₹297.97 crore, making KHL a subsidiary (credit confirmation received May 18, 2026).
Stake Acquisition
Max Healthcare acquired ~58.28% stake in 250‑bed Kalinga Hospital Ltd for ~₹297.97 Crore, financed via a Senior Secured Term Loan (ECB facility up to ₹300 Cr); KHL is now a subsidiary (equity credited today).
Earnings Call
Max Healthcare will host an investor and analyst earnings call on May 22, 2026 at 11:00 AM IST to discuss Q4 & FY26 financial results (to be declared May 21, 2026); senior management will participate.
Board Meeting - Results
Max Healthcare will hold a Board meeting on 21 May 2026 to consider and approve standalone and consolidated financial results for the quarter and FY ended 31 Mar 2026 and to consider recommending a final dividend; trading window closed until 48 hours after declaration.
Bearish
9
Neutral
2
Bullish
3
Bearish
11
Neutral
2
Bullish
33
Bearish
2
Neutral
0
Bullish
30
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
8094.85 | 1,15,402 Cr | 64.04 | 12.70 | 0.16 | 18.39 | 16.07 | 8.50 | ||
994.60 | 1,03,826 Cr | 73.16 | 10.33 | 0.14 | 13.50 | 12.81 | 8.72 | ||
915.00 | 72,484 Cr | 75.52 | 7.69 | 0.10 | 10.75 | 12.26 | 6.53 | ||
742.00 | 38,779 Cr | 99.91 | 9.17 | 0.40 | 8.48 | 10.10 | 5.27 | ||
1880.95 | 38,488 Cr | 49.41 | 9.48 | 0.24 | 20.82 | 17.75 | 10.07 | ||
1244.00 | 33,221 Cr | 59.70 | 8.39 | 0.00 | 14.05 | 15.26 | 9.38 | ||
680.00 | 29,652 Cr | 122.83 | 13.19 | 0.00 | 10.74 | 7.99 | 3.12 | ||
| Median: 7 Co. | — | 994.60 | 38,779 Cr | 73.16 | 9.48 | 0.14 | 13.50 | 12.81 | 8.50 |
Max Healthcare Institute Limited operates a network of multi‑speciality and super‑speciality hospitals, plus two strategic business units (Max Lab and Max@Home); the Group runs ~20 facilities with ~5,200 beds, combining owned, managed and partner hospitals across major Indian metros and select PPP arrangements in Punjab.
Q3 FY26 network gross revenue reached ₹2,608 crore (+10% YoY) with Network Operating EBITDA of ₹648 crore (+4% YoY) and Network PAT of ₹344 crore (+9% YoY) after two exceptional items totaling ₹55 crore, reflecting steady profitability despite payor and regulatory headwinds.
Max is aggressively expanding capacity: multiple brownfield towers were partially commissioned with strong early EBITDA margins (~31%–39%), a staggered acquisition in Pune for ~450 beds, and a roadmap to nearly double bed capacity over the next 4–5 years, implying significant future revenue visibility and capital deployment.
Regulatory and payor dynamics materially affected margins this quarter: CGHS tariff revisions, discontinuation of high‑value patented chemotherapy for institutional patients, a GST rate change, and temporary disruption in cashless insurer services altered payor mix and lowered sequential EBITDA margins.
Digital and adjacency businesses are meaningful: digital channels contributed ~₹803 crore (~31% of gross revenue) in Q3 and Max@Home and Max Lab posted robust growth (+23% and +13% YoY respectively), signalling diversified revenue streams and stronger patient acquisition funnels outside core inpatient services.
Healthcare Services
Hospital
1,04,230 Cr
Low Risk
73.4
60.1
2.1
10.3
1,314.30
903.50
Sales CAGR
Profit CAGR
ROE
ROCE
